Wells Fargo analyst Mohit Bansal raised the firm’s price target on Regeneron to $860 from $800 and keeps an Overweight rating on the shares. The firm notes its deep-dive indicates higher probability of upcoming COPD trial working.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on REGN:
- Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review
- 3 Super Profitable S&P 500 Stocks to Buy, Other Than ExxonMobil
- EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA
- Regeneron’s Eylea injection approved by FDA for treatment of preterm infants
- Regeneron named ‘Catalyst Driven Idea’ at Morgan Stanley ahead of COPD data